Abstract
There is a steady rise in the mean age of patients affected by heart disease undergoing cardiac surgery. However senescent myocardium has reduced tolerance to ischemic stress and there are clear indications about age-associated deficit in myocardial performance after operatory stress. CoQ10 improve several conditions related to bioenergetic deficit or increased exposure to oxidative stress. The use of ubiquinol, the reduced form of CoQ10, is promising in these clinical settings, on the basis of its superior bioavailability and of the alleged impaired CoQ10-reducing capacity in the elderly. In this study clinical and biochemical effects of ubiquinol were evaluated in 46 patients undergoing aortic valve replacement. They, affected by severe aortic stenosis, were randomized into 2 groups, placebo and CoQ10 group supplemented with 400 mg/die of ubiquinol starting, 7 days before surgery and continuing for 1 month after cardiac intervention. CoQ10 levels, its oxidative status and IL-6, TNF-alpha and S100 protein concentration in plasma were assessed. Moreover, main cardiac adverse effects in the postoperatory phase, NYHA class, contractility and myocardial hypertrophy were evaluated. Ubiquinol treatment improve basal (before surgery) oxidative status of CoQ10 and considerably mitigate increased oxidation related to the operation.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call